Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A multicenter, multinational, placebo controlled, randomized phase II/III clinical trial of cannabidiol for the treatment of acute graft-versus-host-disease (GVHD)

Trial Profile

A multicenter, multinational, placebo controlled, randomized phase II/III clinical trial of cannabidiol for the treatment of acute graft-versus-host-disease (GVHD)

Status: Planning
Phase of Trial: Phase II/III

Latest Information Update: 21 Jun 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cannabidiol (Primary)
  • Indications Graft-versus-host disease
  • Focus Registrational; Therapeutic Use
  • Sponsors Kalytera Therapeutics
  • Most Recent Events

    • 21 Jun 2018 According to a Kalytera Therapeutics media release, this trial will initiate later in 2018.
    • 21 Jun 2018 According to a Kalytera Therapeutics media release, the Principal Investigator of this study is Edmund Waller, M.D., PhD., Professor, Hematology and Medical Oncology, Medicine, and Pathology at Emory University School of Medicine, and Director, Division of Stem Cell Transplantation and Immunotherapy at Winship Cancer Institute of Emory University.
    • 15 Jun 2018 According to a Kalytera Therapeutics media release, The Salzman Group will provide clinical study management services for this trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top